{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:27:25Z","timestamp":1786976845012,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T00:00:00Z","timestamp":1460505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>\n                    In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B\u2010lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was prospectively investigated in 262 AML patients to determine its prognostic value. Flow cytometric HG detection was performed in bone marrow aspiration after intensive chemotherapy at the time of hematological recovery. Patients with HGs in bone marrow samples had a significantly better relapse\u2010free survival (RFS) and overall survival (OS) than patients without HGs (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0021, and\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0016). Detectable HGs independently predicted RFS (HR\u2009=\u20090.61, 95%CI: 0.42\u2009\u2212\u20090.89,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012) and OS (HR\u2009=\u20090.59, 95%CI: 0.38\u2009\u2212\u20090.92, 0.019) controlling for age, ELN classification, the number of chemotherapy cycles to achieve CR, performance status, secondary AML and flow cytometric minimal residual disease (MRD). In intensively treated AML, individual determination of HGs could be useful to stratify the optimal risk\u2010adapted therapeutic strategy after induction chemotherapy. Am. J. Hematol. 91:566\u2013570, 2016. \u00a9 2016 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ajh.24350","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T18:51:42Z","timestamp":1456944702000},"page":"566-570","source":"Crossref","is-referenced-by-count":9,"title":["The prognostic value of hematogones in patients with acute myeloid leukemia"],"prefix":"10.1002","volume":"91","author":[{"given":"Sylvain P.","family":"Chantepie","sequence":"first","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Parienti","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Clinical Research CHU Caen, Cote de Nacre Avenue 14000 France"},{"name":"Caen Normandie University, Medical school Caen F\u201014000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Salaun","sequence":"additional","affiliation":[{"name":"Hematology Laboratory CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Benabed","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cheze","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Claire","family":"Gac","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyacinthe","family":"Johnson\u2010Ansah","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"},{"name":"Caen Normandie University, Medical school Caen F\u201014000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Pierre","family":"Vilque","sequence":"additional","affiliation":[{"name":"Department of Hematology Baclesse Cancer Centre Caen, General Harris Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumedaly","family":"Reman","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Caen, Cote de Nacre Avenue 14000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1746"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.3948"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0532"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404032"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2498"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400732"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.024"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295378"},{"key":"e_1_2_7_10_1","first-page":"1435","article-title":"Prognostic impact of high hematogones in acute myeloid leukemia","volume":"120","author":"Pereira D","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2652"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-349258"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403405"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403138"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577593"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23893"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","unstructured":"K\u00f6hnkeT SauterD RingelK et al. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse2015;29:377\u2013386.","DOI":"10.1038\/leu.2014.186"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1525-y"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12151"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","unstructured":"ChantepieSP DugueAE ChevallierPet al. Prognostic Impact of Bone Marrow B Lymphocyte Precursors (hematogones) Detection in 95 Acute Lymphoblastic Leukemia Cases. ASH Annual Meeting Abstracts2012;120:4791.","DOI":"10.1182\/blood.V120.21.4791.4791"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409607"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","unstructured":"BacherU ChristopeitM HeilandA et al. Prognostic Impact of Physiological B\u2010Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post\u2010Transplant Period in Patients with AML. ASH Annual Meeting Abstracts2012;120:1406.","DOI":"10.1182\/blood.V120.21.1406.1406"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.11.015"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.11.008"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.05.019"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24350","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:30:23Z","timestamp":1695472223000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/ajh.24350"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24350","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,13]]}}}